Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sartorius Stedim Biotech SA Confirms FY 2013 Revenue Guidance


Tuesday, 23 Jul 2013 01:05am EDT 

Sartorius Stedim Biotech SA announced that, based on its results from the first half of fiscal year 2013, it confirms its full-year targets for fiscal year 2013 and expects its revenue to grow by approximately 8% to 11% in constant currencies. The Company reported a revenue of EUR 544 million for fiscal year 2012. According to I/B/E/S Estimates, analysts on average are expecting the Company to report revenue of EUR 597 million for fiscal year 2013. 

Company Quote

127.65
-1.25 -0.97%
11:01am EDT